<DOC>
	<DOCNO>NCT01026116</DOCNO>
	<brief_summary>Manifold data reveal young breast cancer patient characterize aggressive clinical history . The purpose study evaluate efficacy safety different strategy incorporate paclitaxel anthracycline-based regimen young breast cancer patient .</brief_summary>
	<brief_title>A Randomized Trial Comparing Epirubicin/Cyclophosphamide Followed Weekly Paclitaxel Versus Epirubicin/Paclitaxel Followed Weekly Paclitaxel Adjuvant Therapy Operable Breast Cancer Patients Less Than 40 Years Old</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Epirubicin</mesh_term>
	<criteria>Female patient , age 18~40 Unilateral , operable , histologically confirm adenocarcinoma breast Stage IIII Primary surgery clear margin plus axillary dissection Able start protocol Rx within 4 week surgery HER2 positive ( IHC 3+ OR FISH+ ) sequential use trastuzumab follow chemotherapy Occult breast cancer histologically confirm primary invasive carcinoma DICS microinvasion ipsilateral breast surgery ECOG performance status 01 Adequate cardiac , renal , hepatic hematologic function Metastatic disease Bilateral breast cancer ( synchronous metachronous ) Prior radiation therapy , hormonal therapy chemotherapy breast cancer Previous cancer ( except treat basal cell squamous cell carcinoma skin cancer uterine cervix ) HER2 positive ( IHC 3+ OR FISH+ ) concurrence use adjuvant chemotherapy trastuzumab Documented history cardiac disease contradiction anthracyclines Concurrent serious illness Peripheral neuropathy CTC grade &gt; 1 History hypersensitivity drug formulate Cremophor EL polyoxyethylated castor oil ) , vehicle use commercial paclitaxel formulation Pregnancy lactation</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>December 2009</verification_date>
</DOC>